Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The study titled “A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound” looks at how long fasting and pausing tirzepatide changes stomach contents after a meal. It matters because safety around procedures that use sedation is now a key focus for users of GLP-1 style drugs.
The trial tests tirzepatide, a once weekly injectable drug also known as LY3298176. It is already central to Eli Lilly’s push in Type 2 diabetes and obesity and this work aims to clarify how it affects the stomach when dosing is briefly stopped.
This is an interventional Phase 1 study with two groups, one with Type 2 diabetes and one with overweight or obesity without diabetes. There is no randomization or blinding, and the main goal is basic science, using ultrasound to see how much food and fluid stay in the stomach.
The study was first submitted on 10 Dec 2025 and remains in recruiting status, showing that enrollment is still underway. The latest update on 02 Mar 2026 signals that protocol details and timelines have been recently reviewed and confirmed by Eli Lilly.
For investors, this update speaks more to risk management than near term sales upside for LLY. Clearer data on gastric emptying and fasting rules could ease concerns among doctors and regulators, support broader use of tirzepatide, and sharpen Lilly’s edge against obesity rivals like NVO and other GLP-1 players.
The study is actively recruiting and has been recently updated, with full details available on the ClinicalTrials portal under identifier NCT07299084.
To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.